Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day
12 Décembre 2024 - 2:00PM
Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug
creation company, today announced updates and progress across its
internal pipeline of proprietary Drug Creation programs, as well as
new breakthroughs demonstrated by Absci’s AI Integrated Drug
Creation™ platform. Absci leadership and a series of distinguished
guest speakers will be presenting on these updates today at Absci’s
2024 R&D Day.
“Today’s updates represent another major step
forward for Absci, as we continue to demonstrate our leadership in
de novo AI antibody design, which is driving significant
advancements in our internal and partnered programs,” said Sean
McClain, Founder and CEO. “We are excited to showcase the target
and significant opportunities we see for ABS-201, present new data
for ABS-101 and ABS-301, and introduce ABS-501 to our pipeline.
ABS-201, a potential treatment for male and female pattern hair
loss, represents an opportunity to unlock an entirely new category
of therapy for a substantial consumer-driven market with
significant clinical unmet need. And as we near the end of 2024, we
see next year as an opportunity to reach multiple milestones across
our internal portfolio, and maintain a robust pipeline of potential
partners across the Pharma and broader healthcare industry
landscape.”
Speakers and topics to be covered during today’s
presentation include:
Absci Leadership
- Sean McClain, Founder & CEO, Absci
- Andreas Busch, PhD, Chief
Innovation Officer, Absci
- Zach Jonasson, PhD, Chief
Financial Officer & Chief Business Officer, Absci
- Amaro Taylor-Weiner, PhD,
Chief AI Officer, Absci
- Christian Stegmann, PhD, SVP Drug Creation,
Absci
Guest Presenters
- Sir Mene Pangalos,
PhD, Biopharmaceutical Executive; Board Director,
Absci; Co-Chair, Absci Scientific Advisory Board
- Dr. Luis Diaz, MD,
Head of the Division of Solid Tumor Oncology, Memorial Sloan
Kettering Cancer Center; Advisor, Absci
- Dr. Dennis Slamon, MD,
PhD, Chief of Division of Hematology and Oncology, UCLA
Medicine
- Karl
Ziegelbauer, PhD, Chief Scientific
Officer, Almirall
- Dr. Anthony Rossi,
MD, Attending Dermatologist, Memorial Sloan Kettering
Cancer Center; Professor of Dermatology, Weill Cornell Medical
College; Advisor, Absci
- Mike Jafar,
Medical Aesthetics Executive; Advisor, Absci
ABS-201ABS-201 is a potential best-in-class
anti-PRLR antibody in development for androgenic alopecia, an
indication with significant clinical unmet need and a large
potential patient population of approximately 80 million
individuals in the U.S. alone.
- Absci has nominated a drug
candidate with preclinical profile suggesting:
- High affinity and potency
- Favorable safety and
immunogenicity
- Extended half-life for convenient
infrequent dosing
- Excellent developability and
manufacturability
- Preclinical model demonstrates
improved hair regrowth compared to minoxidil
- ABS-201 has potential to offer a
safe option as compared to current standard of care
- Anticipate initiation of Phase 1
clinical trial in 1H 2026
ABS-101ABS-101 is a potential best-in-class
anti-TL1A antibody that demonstrates high affinity and potency,
ability to bind the monomer and trimer of TL1A, anticipated low
immunogenicity, high bioavailability in non-human primates, and
potential to be administered subcutaneously with an anticipated
dosing interval of 8-12 weeks, or even less frequently.
- ABS-101 shows reduced
internalization of TL1A complexes in in vitro THP-1 immunogenicity
tests compared to a competitor molecule with a high clinical
anti-drug antibody (ADA) rate.
- This suggests a lower chance of
developing ADAs in clinical settings, as internalization of
mAb:TL1A complexes could contribute to immune activation and ADA
formation.
- 13-week GLP toxicology studies: No
treatment-related adverse findings during in-life phase and
necropsy were observed; histopathology is pending.
- Anticipate initiation of Phase 1
clinical trial in 1H 2025
ABS-301ABS-301 is a potential
first-in-class antibody for an undisclosed immuno-oncology target,
discovered through Absci’s AI Reverse Immunology target discovery
platform.
- Expression of ABS-301’s target
suggests broad potential in squamous cell carcinomas and
beyond.
- For this program, Absci has
optimized an antibody lead with high affinity and potency, and
anticipates selecting a drug candidate in 1H 2025.
ABS-501ABS-501 is a potential
best-in-class novel AI-designed anti-HER2 antibody.
- Absci has identified lead molecules
using its zero-shot de novo AI technology with the following
characteristics:
- Novel epitope interactions
- Increased or equivalent affinity to
trastuzumab in preclinical settings
- Efficacious against a
trastuzumab-resistant xenograft tumor expressing wild-type
HER2
- Good developability
- Anticipate selection of a drug
candidate in 2025, and multiple paths for therapeutic development
of this program are under consideration.
AI Platform Breakthrough Demonstrated
through Collaboration with California Institute of
Technology
- Absci has achieved
a breakthrough by de novo designing an antibody that targets a
previously difficult-to-drug epitope in the HIV “caldera” region.
This breakthrough potentially aids the development of a universal
HIV vaccine.
- Leveraging its proprietary de novo
antibody design model AbsciDesign, Absci created antibodies
targeting a highly conserved and structurally challenging region of
the HIV gp120 protein. The “caldera” region, uniquely accessible
only in the open conformation of gp120, has remained untargeted by
previous broadly neutralizing antibodies.
- Preliminary screening data
indicates that designs bind clades A, B, and C with selective
binding to open conformation. Antibodies from this study will be
further experimentally evaluated to confirm fidelity of the de novo
designed structure and epitope specificity.
- Successful
creation of these antibodies marks a potential pivotal milestone in
HIV vaccine research and underscores the capability of AbsciDesign
to target conserved epitopes that were previously considered out of
reach.
A live and archived webcast of Absci’s 2024
R&D Day may be accessed via the company’s investor relations
website at: investors.absci.com.
About AbsciAbsci is a
data-first generative AI drug creation company that combines AI
with scalable wet lab technologies to create better biologics for
patients, faster. Our Integrated Drug Creation™ platform
unlocks the potential to accelerate time to clinic and increase the
probability of success by simultaneously optimizing multiple drug
characteristics important to both development and therapeutic
benefit. With the data to train, the AI to create, and the wet lab
to validate, we can screen billions of cells per week, allowing us
to go from AI-designed candidates to wet lab-validated candidates
in as little as six weeks. Absci’s headquarters is in Vancouver,
WA, with our AI Research Lab in New York City and an Innovation
Center in Zug, Switzerland. Visit www.absci.com and follow us
on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Investor ContactAlex KhanVP,
Finance & Investor Relationsinvestors@absci.com
Media
Contactpress@absci.com
AbSci (NASDAQ:ABSI)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
AbSci (NASDAQ:ABSI)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024